TAPT1 antisense RNA 1 (TAPT1-AS1)

TAPT1 antisense RNA 1 (TAPT1-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the TAPT1 gene[1]. It does not encode a protein, but is implicated in the regulation of gene expression, including autophagy and cell survival, and has been identified with oncogenic functions in several cancer types, such as colorectal cancer and neuroendocrine prostate cancer[2][4]. TAPT1-AS1 is often upregulated in metastatic and aggressive tumors, promoting cancer cell invasion, metastasis, and angiogenesis by stabilizing the mRNA for vascular endothelial growth factor A (VEGFA)[4]. Despite its proximity and antisense orientation to TAPT1, TAPT1-AS1 does not regulate TAPT1 protein expression directly and is not involved in TAPT1-related congenital disorders[1]. TAPT1-AS1 has been proposed as a potential therapeutic target for the treatment of neuroendocrine tumors and metastatic cancers[2][4]. No approved drugs yet specifically target TAPT1-AS1, but its modulation may influence cancer cell viability and disease progression. Conflicting reports exist regarding its tumor-suppressive versus oncogenic roles in different cancer types[4].

Other names

TAPT1-AS1FLJ39653TAPT1 antisense RNA 1 (head to head)

Drugs targeting TAPT1-AS1 would likely act via inhibition of lncRNA function, suppression of cancer cell survival, inhibition of autophagy, or disruption of angiogenic pathways